Cargando…

1124. Impact of a Best Practice Advisory for Pediatric Patients with Staphylococcus aureus Bloodstream Infection

BACKGROUND: Infectious diseases (ID) consultation and use of optimal antibiotic therapy have been shown to improve outcomes of patients with Staphylococcus aureus bloodstream infection (SA-BSI). We investigated the ability of an electronic medical record (EMR)-based best practice advisory (BPA) to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Lloyd, Elizabeth C, Martin, Emily T, Dillman, Nicholas, Nagel, Jerod, Gandhi, Tejal N, Tribble, Alison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811168/
http://dx.doi.org/10.1093/ofid/ofz360.988
_version_ 1783462415434776576
author Lloyd, Elizabeth C
Martin, Emily T
Dillman, Nicholas
Nagel, Jerod
Gandhi, Tejal N
Tribble, Alison
author_facet Lloyd, Elizabeth C
Martin, Emily T
Dillman, Nicholas
Nagel, Jerod
Gandhi, Tejal N
Tribble, Alison
author_sort Lloyd, Elizabeth C
collection PubMed
description BACKGROUND: Infectious diseases (ID) consultation and use of optimal antibiotic therapy have been shown to improve outcomes of patients with Staphylococcus aureus bloodstream infection (SA-BSI). We investigated the ability of an electronic medical record (EMR)-based best practice advisory (BPA) to enhance adherence to these practices for pediatric patients with SA-BSI. METHODS: An EMR-based BPA for SA-BSI (Figure 1) was implemented on 8/1/2017, recommending ID consultation and optimal therapy based on mecA gene rapid testing (vancomycin if mecA-positive; cefazolin or nafcillin if mecA-negative). We conducted a quasi-experimental pre/post study to evaluate impact of the BPA. Patients <21 years old admitted to C.S. Mott Children’s Hospital with SA-BSI during the pre- (1/2015 – 7/2017) and post-intervention (8/2017 – December 2018) periods were included. Demographic and clinical data were collected via chart review. Receipt of ID consult and optimal therapy before and after intervention were compared using interrupted time series (ITS) analysis with segmented regression. Time to optimal therapy was compared with segmented Cox regression. RESULTS: We included 99 SA-BSI episodes (70.7% pre-intervention and 29.3% post-intervention). Pre-intervention, 68.6% of patients received an ID consult compared with 93.1% post-intervention, but this was not significant with ITS analysis (Figure 2). The proportion of patients receiving optimal therapy did not significantly increase following the intervention, but time to optimal therapy significantly decreased (Figure 3). The median time to optimal therapy decreased from 26.1 hours to 5.5 hours. Cox regression showed both an immediate decrease in time to optimal therapy (HR 3.9, P = 0.009), followed by a continued decrease over time. CONCLUSION: Following implementation of a novel EMR-based intervention, ID consultation for SA-BSI increased, although this was not statistically significant due to a pre-existing trend of increasing ID consults over time. Implementation of the BPA was associated with a significant decrease in time to optimal therapy, likely due to a combination of increasing ID consultation and antibiotic guidance provided by the BPA. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures
format Online
Article
Text
id pubmed-6811168
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68111682019-10-29 1124. Impact of a Best Practice Advisory for Pediatric Patients with Staphylococcus aureus Bloodstream Infection Lloyd, Elizabeth C Martin, Emily T Dillman, Nicholas Nagel, Jerod Gandhi, Tejal N Tribble, Alison Open Forum Infect Dis Abstracts BACKGROUND: Infectious diseases (ID) consultation and use of optimal antibiotic therapy have been shown to improve outcomes of patients with Staphylococcus aureus bloodstream infection (SA-BSI). We investigated the ability of an electronic medical record (EMR)-based best practice advisory (BPA) to enhance adherence to these practices for pediatric patients with SA-BSI. METHODS: An EMR-based BPA for SA-BSI (Figure 1) was implemented on 8/1/2017, recommending ID consultation and optimal therapy based on mecA gene rapid testing (vancomycin if mecA-positive; cefazolin or nafcillin if mecA-negative). We conducted a quasi-experimental pre/post study to evaluate impact of the BPA. Patients <21 years old admitted to C.S. Mott Children’s Hospital with SA-BSI during the pre- (1/2015 – 7/2017) and post-intervention (8/2017 – December 2018) periods were included. Demographic and clinical data were collected via chart review. Receipt of ID consult and optimal therapy before and after intervention were compared using interrupted time series (ITS) analysis with segmented regression. Time to optimal therapy was compared with segmented Cox regression. RESULTS: We included 99 SA-BSI episodes (70.7% pre-intervention and 29.3% post-intervention). Pre-intervention, 68.6% of patients received an ID consult compared with 93.1% post-intervention, but this was not significant with ITS analysis (Figure 2). The proportion of patients receiving optimal therapy did not significantly increase following the intervention, but time to optimal therapy significantly decreased (Figure 3). The median time to optimal therapy decreased from 26.1 hours to 5.5 hours. Cox regression showed both an immediate decrease in time to optimal therapy (HR 3.9, P = 0.009), followed by a continued decrease over time. CONCLUSION: Following implementation of a novel EMR-based intervention, ID consultation for SA-BSI increased, although this was not statistically significant due to a pre-existing trend of increasing ID consults over time. Implementation of the BPA was associated with a significant decrease in time to optimal therapy, likely due to a combination of increasing ID consultation and antibiotic guidance provided by the BPA. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures Oxford University Press 2019-10-23 /pmc/articles/PMC6811168/ http://dx.doi.org/10.1093/ofid/ofz360.988 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Lloyd, Elizabeth C
Martin, Emily T
Dillman, Nicholas
Nagel, Jerod
Gandhi, Tejal N
Tribble, Alison
1124. Impact of a Best Practice Advisory for Pediatric Patients with Staphylococcus aureus Bloodstream Infection
title 1124. Impact of a Best Practice Advisory for Pediatric Patients with Staphylococcus aureus Bloodstream Infection
title_full 1124. Impact of a Best Practice Advisory for Pediatric Patients with Staphylococcus aureus Bloodstream Infection
title_fullStr 1124. Impact of a Best Practice Advisory for Pediatric Patients with Staphylococcus aureus Bloodstream Infection
title_full_unstemmed 1124. Impact of a Best Practice Advisory for Pediatric Patients with Staphylococcus aureus Bloodstream Infection
title_short 1124. Impact of a Best Practice Advisory for Pediatric Patients with Staphylococcus aureus Bloodstream Infection
title_sort 1124. impact of a best practice advisory for pediatric patients with staphylococcus aureus bloodstream infection
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811168/
http://dx.doi.org/10.1093/ofid/ofz360.988
work_keys_str_mv AT lloydelizabethc 1124impactofabestpracticeadvisoryforpediatricpatientswithstaphylococcusaureusbloodstreaminfection
AT martinemilyt 1124impactofabestpracticeadvisoryforpediatricpatientswithstaphylococcusaureusbloodstreaminfection
AT dillmannicholas 1124impactofabestpracticeadvisoryforpediatricpatientswithstaphylococcusaureusbloodstreaminfection
AT nageljerod 1124impactofabestpracticeadvisoryforpediatricpatientswithstaphylococcusaureusbloodstreaminfection
AT gandhitejaln 1124impactofabestpracticeadvisoryforpediatricpatientswithstaphylococcusaureusbloodstreaminfection
AT tribblealison 1124impactofabestpracticeadvisoryforpediatricpatientswithstaphylococcusaureusbloodstreaminfection